Plus Therapeutics Stock News

AUSTIN, Texas, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics

These penny stocks climbed during premarket trading, here's why The post Hot Penny Stocks to Watch Right Now That Are Moving in Premarket appeared first on Penny Stocks to Buy, Picks, News and Informa

Plus Therapeutics, Inc (NASDAQ: PSTV) has entered into an agreement with The University of Texas Health Science Center at San Antonio for a worldwide exclusive license to develop and commercialize

Check these three biotech penny stocks out for your watchlist right now The post Best Biotech Penny Stocks to Buy Now? 3 to Watch in January appeared first on Penny Stocks to Buy, Picks, News and Info

The research study presented here is an intelligent take on the global Cord Blood Stem Cells Market that explains important aspects such as competition, segmentation, and regional growth in great detail. Accuracy and preciseness are two of the key features

AUSTIN, Texas, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics

Plus Therapeutics Inc (NASDAQ: PSTV ) released interim data from Phase 1 ReSPECT-GBM trial in patients with recurrent glioblastoma (GBM) of Rhenium-186 NanoLiposome (186RNL). According to the interim data, 186RNL delivered via convection-enhanced delivery (CED) was well-tolerated with favorable overall survival at higher absorbed radiation doses. A positive correlation was observed between overall survival and Full story available on Benzinga.com

Data Bridge Market research presents the top quality and comprehensive Active Wound Care research report which provides clear insights into market dynamics and prospects the whole market including global production, revenue forecast, value and volume. This Active Wound Care

Complete study of the global Systemic Sclerosis Treatments market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of

Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q3 2021 Results - Earnings Call Transcript

Patient accrual for the Phase 1 dose escalation clinical trial of 186 RNL (ReSPECT-LM) is expected in the fourth quarter of 2021

AUSTIN, Texas, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics

AUSTIN, Texas, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherape

AUSTIN, Texas, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics

AUSTIN, Texas, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics